Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of BIOVAXYS TECHNOLOGIESLOGY CORP
No Price
Closing Price XCNQ 28.04.2026:
0,06 CAD
28.04.2026 20:00
Current Prices from BIOVAXYS TECHNOLOGIESLOGY CORP
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
UTC
BVAXF
USD
28.04.2026 20:00
0,05 USD
-0,0004 USD
-0,76 %
CSE LISTED
BIOV.CN
CAD
28.04.2026 19:51
0,06 CAD
-0,01 CAD
-14,29 %
Share Float & Liquidity
Free Float88,52 %
Shares Float25,81 M
Shares Outstanding29,15 M
Company Profile for BIOVAXYS TECHNOLOGIESLOGY CORP Share
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
